Antimicrobial resistance (AMR) is one of the biggest threats facing the world but arguably not enough is being done by both pharma companies and governments around the world.
In the latest Meet the maker, EPM speaks to Ben Wylie, senior product manager at ChargePoint Technology who talks about the challenges of the industry and what it needs to remain innovative.
Jennifer Lopez, director, solutions delivery at Maetrics discusses why heightened due diligence is needed for pharmaceutical manufacturers during mergers and acquisitions.
Kathryn Moon, Life Science Risk & Insurance specialist at UK broker Gallagher, looks at why it can be essential for businesses in the industry to have a robust insurance policy in place to protect it.
Global specialty pharma company, Theramex, and private pharma company, Endoceutics, have entered into a definitive agreement for the exclusive licensing of Intrarosa (Prasterone) in Europe, Australia, Russia and the Ukraine.
Here, we have a chat with Billy Amzal, PhD, X-Eng, MSc, MPA, who has been appointed as Certara’s senior vice president, decision and real-world data analytics.
In this latest instalment of ‘Meet the maker’, we sit down with Peter Neve, chief marketing officer at ACG — a company that offers integrated manufacturing solutions for the pharmaceutical industry.
CDMO, Recipharm, has acquired Sanofi’s manufacturing centre and business located in Holmes Chapel, which will provide the company with a platform to take advantage of the growing respiratory drug market.
Contract research organisation (CRO), Reaction Biology, has partnered with an open science drug discovery and development company, M4K Pharma, in the fight against diffuse intrinsic pontine glioma (DIPG) — a rare paediatric brain cancer.
Here, Mark Tempest, VWV partner in the Insolvency and Restructuring and Pharmaceuticals and Life Sciences teams, looks at the construction giant’s case in more detail and what pharma and life sciences should consider in order to protect themselves.
